FDA Warns Telehealth Companies Against Misleading Claims on Compounded Weight-Loss Drugs

‘Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of consistent quality,’ the agency said.

The Food and Drug Administration in White Oak, Md., on June 5, 2023. Madalina Vasiliu/The Epoch Times

The U.S. Food and Drug Administration (FDA) on June 16 issued a series of warning letters to telehealth companies for promoting compounded weight-loss and diabetes drugs with “false and misleading” claims.

The agency said it had sent 25 warning letters to telehealth companies such as Ready Med, Maximus Health, and Medica Weight Loss over claims that their compounded GLP-1 drugs had been evaluated for safety.